COYA Stock Overview
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Coya Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.78 |
| 52 Week High | US$10.69 |
| 52 Week Low | US$3.21 |
| Beta | 0 |
| 1 Month Change | -11.67% |
| 3 Month Change | 44.17% |
| 1 Year Change | 75.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 92.12% |
Recent News & Updates
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Recent updates
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17Shareholder Returns
| COYA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.2% | 2.7% | 0.3% |
| 1Y | 76.0% | 2.9% | 24.2% |
Return vs Industry: COYA exceeded the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: COYA exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| COYA volatility | |
|---|---|
| COYA Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COYA's share price has been volatile over the past 3 months.
Volatility Over Time: COYA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 8 | Howard Berman | www.coyatherapeutics.com |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company’s product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.
Coya Therapeutics, Inc. Fundamentals Summary
| COYA fundamental statistics | |
|---|---|
| Market cap | US$126.60m |
| Earnings (TTM) | -US$7.99m |
| Revenue (TTM) | US$6.00m |
21.4x
P/S Ratio-16.1x
P/E RatioIs COYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COYA income statement (TTM) | |
|---|---|
| Revenue | US$6.00m |
| Cost of Revenue | US$5.50m |
| Gross Profit | US$500.68k |
| Other Expenses | US$8.49m |
| Earnings | -US$7.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 8.34% |
| Net Profit Margin | -133.08% |
| Debt/Equity Ratio | 0% |
How did COYA perform over the long term?
See historical performance and comparison